Drug intelligence / Profile preview

ADB-103

Development stage: Preclinical
Lead developer: Adolore Biotherapeutics
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Peptides
Administration: Intraarticular

Overview

ADB-103 is a gene therapy being developed by Adolore BioTherapeutics for the treatment of chronic pain, specifically osteoarthritis (OA) hip pain. It utilizes a novel, non-opioid gene therapy (ADLR-1001) based on replication-defective Herpes Simplex Virus (rdHSV) vectors to deliver CA8* (carbonic anhydrase-like analgesic peptides, CA8 variants). This therapy is designed to locally target peripheral sensory nerve fibers that are hyperexcitable due to sensitization and inflammation, aiming to provide pain relief.

Other names: OA Hip Pain

Targets

CRCs (Intracellular calcium release channels)KCNQ (Potassium voltage-gated channel subfamily Q (Kv7))

Beyond the preview

Go deeper on ADB-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADB-103.

Explore the full profile